NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Abedalrahman Maen Addassi: Edoxaban’s Journey Shows How Targeted Pharmacology and Real-World Data Converge
Abedalrahman Maen Addassi/LinkedIn
Oct 16, 2025, 05:58

Abedalrahman Maen Addassi: Edoxaban’s Journey Shows How Targeted Pharmacology and Real-World Data Converge

Abedalrahman Maen Addassi, Pharmacist, shared a post on LinkedIn:

”Innovation in Anticoagulation: Edoxaban by Daiichi Sankyo

In a world where stroke prevention and venous thromboembolism management are critical, Edoxaban (Savaysa) stands out as a once-daily oral anticoagulant that’s reshaping clinical practice.

  • FDA Approval Date: January 8, 2015 A B
  • Mechanism of Action: Edoxaban is a direct Factor Xa inhibitor, selectively blocking a key step in the coagulation cascade to prevent thrombus formation C.

Indications:

  • Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial parenteral anticoagulation A B

Side Effects:

  • Most common: bleeding, including gastrointestinal and intracranial hemorrhage
  • Others: anemia, rash, liver enzyme elevation—requiring careful renal function monitoring, especially in patients with CrCL >95 mL/min B

How Does It Compare?

  • Warfarin: Edoxaban showed non-inferior efficacy with lower rates of major bleeding in ENGAGE AF-TIMI 48 trial B
  • Rivaroxaban and Apixaban: All are Factor Xa inhibitors, but edoxaban offers once-daily dosing and a favorable bleeding profile in select populations
  • Dabigatran: A direct thrombin inhibitor—different mechanism, twice-daily dosing, and higher GI bleeding risk

Backed by global trials like ENGAGE AF-TIMI 48 and Hokusai-VTE, edoxaban continues to expand its footprint across more than 40 countries C.

As a recent pharmacy graduate passionate about medical information and therapeutic innovation, I find edoxaban’s journey a powerful example of how targeted pharmacology and real-world data can converge to improve patient outcomes.

Let’s connect if you’re working in anticoagulation, clinical trials, or medical affairs—I’d love to exchange insights!”

Stay updated with Hemostasis Today.

Abedalrahman Maen Addassi Anticoagulation bleeding Daiichi Sankyo deep vein thrombosis DVT edoxaban Factor Xa inhibitor Health hemorrhage Hemostasis Today Medicine Oral Anticoagulant PE Pulmonary embolism Savaysa
NewsFeed